Karachi, Haleon Pakistan Limited (HALEON), previously known as GlaxoSmithKline Consumer Healthcare, reported no dividend distributions for the year. With a steady EPS of 2.78 for the period January-February 2024 and a paid-up capital of 1,170.55 million rupees, Haleon aims to maintain its market presence since its 2017 listing, focusing on long-term growth and stability in the competitive pharmaceutical sector.